argenx (NASDAQ:ARGX) Upgraded to Hold at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of argenx (NASDAQ:ARGX) from a sell rating to a hold rating in a report published on Wednesday, Marketbeat Ratings reports.

A number of other equities research analysts have also recently commented on the stock. Oppenheimer raised their price objective on shares of argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Truist Financial reaffirmed a “buy” rating and set a $700.00 price objective (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. HC Wainwright raised their price objective on shares of argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target on the stock in a research note on Tuesday, November 12th. Finally, Evercore ISI lifted their price target on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, argenx currently has an average rating of “Moderate Buy” and an average price target of $687.00.

argenx Trading Up 1.9 %

Shares of NASDAQ:ARGX opened at $591.45 on Wednesday. The company has a market cap of $35.94 billion, a PE ratio of -672.10 and a beta of 0.59. argenx has a twelve month low of $349.86 and a twelve month high of $678.21. The company’s 50 day moving average is $639.78 and its 200 day moving average is $595.30.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Equities research analysts predict that argenx will post 3.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GeoWealth Management LLC raised its holdings in shares of argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after acquiring an additional 18 shares during the period. Steward Partners Investment Advisory LLC raised its holdings in shares of argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock worth $234,000 after acquiring an additional 20 shares during the period. SG Americas Securities LLC raised its holdings in shares of argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after acquiring an additional 21 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of argenx by 38.2% during the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after acquiring an additional 21 shares during the period. Finally, Dynasty Wealth Management LLC raised its holdings in shares of argenx by 3.4% during the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock worth $416,000 after acquiring an additional 22 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.